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and non-adherence.
Previously, we and others have used conjoint analysis choice tasks to
assess patients' trade-offs with regard to treatment of rheumatoid ar-
thritis, endocrine therapy for breast cancer, and antidepressants [2–4].
These tasks are realistic in two respects. First, they do not assess mere
preferences but rather trade-off preferences, which are inevitable be-
cause there is no such thing as a perfect treatment. Second, these tasks
directly assess patients' trade-offs rather than assessing the beneﬁts
and drawbacks with independent questions. In a conjoint analysis
choice task, patients are asked to choose between pairs of hypothetical
treatment alternatives (presented left and right). Each time, the left al-
ternative ismore favorable than the right alternative for one character-Efﬁcacious lowering of low-density lipoprotein cholesterol through
prolonged statin therapy has become a major strategy for primary and
secondary prevention of cardiovascular disease. From the perspective
of patients, however, the prophylactic efﬁcacy may be difﬁcult to com-
prehend. It refers to prospective disease prevention at the population
level and an uncertain risk reduction for individual patients. At the
same time, actual side effects may occur and treatment entails a lifelong
regimen.
It is therefore not surprising that a largemeta-analysis demonstrated
that only 54% of patients showed good adherence to statins [1]. We
therefore examined patients' trade-offs between the efﬁcacy, side ef-
fects and other drawbacks of statins using a conjoint analysis choice
task (see www.sawtoothsoftware.com, ‘Technical Papers’ in ‘Support’, MLB, AMS. Data collection and
MLB. Manuscript drafting: HW,
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.menu). Subsequently, we examined associations between trade-offs
istic (e.g. cholesterol lowering) but less favorable than the right
alternative for another characteristic (e.g. muscle pain as a side effect).
Using so-called adaptive conjoint analysis (ACA), the ﬁfteenmost infor-
mative pairs of treatment alternatives were presented to each individu-
al patient. ACA achieves this by means of a computerized tailoring of
pairs of treatment alternatives on the basis of a patient's previous
trade-off choices.
Based on the literature and focus groups,we selected the following 7
treatment characteristics: ‘prevention of myocardial infarction’ and
‘cholesterol lowering’ (beneﬁts), the side effects of ‘muscle and joint
pain’, ‘feeling nauseous and stomach cramps or diarrhea’, and ‘severe
side effects requiring hospital admission e.g. rhabdomyolysis’, as well
as ‘regimen duration’, and ‘restrictions on alcohol consumption’ (draw-
backs). To elicit trade-off choosing, every characteristic was described at
favorable and less favorable levels (e.g. ‘a bit muscle pain’ versus ‘mod-
erate to severe muscle pain’).
From patients' trade-off preferences, we calculated, for each individ-
ual patient, a utility for each level of every treatment characteristic on a
scale ranging from ~−2.5 to +2.5. The higher the utility, the higher
the attractiveness of a level of a treatment characteristic for a patient
(e.g. ‘a bit muscle pain’ was expected to receive a higher utility than
‘moderate to severe muscle pain’). Based on the utility estimates, a rel-
ative importance score for each treatment characteristic was calculated
aswell as a beneﬁt/drawback ratio between the importance of the char-
acteristics reﬂecting beneﬁts and the characteristics reﬂecting draw-
backs in the way as described elsewhere [3,4]. Non-adherence was
measured with two self-report instruments [5,6]. Factor analysis
Table 2
Mean and SD of utilities of treatment attribute levels and relative importance of treatment
attributes.
Treatment attributes and their levels Utilities⁎ Average
importance %†
M SD M SD
Efﬁcacy
Prevention of myocardial infarction 17.2 4.3
In 2/10 people (a ﬁfth) −0.49 0.47
In 5/10 people (half) +0.56 0.45
Cholesterol lowering 14.0 2.9
But above target level −0.37 0.36
At target level +0.44 0.34
Side effects
Muscle and joint pain 19.1 3.2
A bit +0.59 0.44
Moderate to severe −0.52 0.47
Feeling nauseous and stomach
cramps or diarrhea
20.5 2.7
A bit +0.64 0.48
Moderate to severe −0.57 0.50
Severe side effects requiring hospital
admission e.g. rhabdomyolysis
12.4 2.1
1/1000 people +0.40 0.30
2/1000 people −0.33 0.33
Practical aspects
Regimen duration 6.7 1.7
5 years treatment +0.23 0.18
Lifelong treatment −0.16 0.21
Restrictions on alcohol consumption 10.1 3.9
Preferably not −0.26 0.31
2–3 daily units allowed +0.33 0.30
⁎ Utilities estimated on a scale ranging from ~−2.5 to +2.5; the higher the estimated
utility value of an attribute level, the more that attribute level is preferred, e.g. 5 years of
treatment versus lifelong treatment.
†
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tional non-adherence (alpha 0.77, 3 items, range 0–3) and intentional
non-adherence (alpha 0.75, 5 items, range 0–5). In addition, non-
adherence was also calculated from pharmacy reﬁll data as a combina-
tion of adherence measures improves accuracy [7]. The medical ethical
committee approved the study. All participants provided informed
consent.
Two-hundred-twenty-nine patients who were recruited through
pharmacies participated (see Table 1 for demographic and clinical char-
acteristics). Analyses showed that thehighest average importance scores
were seen for ‘muscle and joint pain’ as well as for ‘feeling nauseous and
stomach cramps or diarrhea’ (see Table 2). ‘Prevention of myocardial in-
farction’was on average somewhat less but still substantially important.
‘Cholesterol lowering’ and ‘severe side effects requiring hospital admis-
sion, e.g. rhabdomyolysis’ were on average of intermediate importance.
‘Restrictions on alcohol consumption’ and ‘regimen duration’ were on
average least important. The beneﬁt/drawback ratio showed that ~40%
of the patients valued efﬁcacy equal to or lower than side effects and
other drawbacks. After adjusting for relevant demographic and clinical
characteristics, a higher beneﬁt/drawback ratio was not associated
with decreased unintentional non-adherence (OR 0.3, 95% CI: 0.1–1.2,
Wald = 3.0, p = 0.08), but was associated with decreased intentional
non-adherence (OR 0.1, 95% CI: 0.03–0.40, Wald = 10.0, p b 0.005).
No such association was found between the beneﬁt/drawback ratio
and non-adherence inferred from the pharmacy reﬁll data (OR 1.1, 95%
CI: 0.23–5.2Wald= 0.01, p= 0.92). Theseﬁndingsmake sense because
unintentional non-adherence or amere forgetting or lack of understand-
ing of the regimen is not likely to reﬂect trade-off choosing, whereas in-
tentional non-adherence is, and non-adherence inferred from pharmacy
reﬁll data is likely to reﬂect both forms of non-adherence.
Our ﬁndings suggest thatmany patients do not consider the prospec-
tive efﬁcacy of statins to outweigh their side effects and other drawbacks.Table 1
Demographic and clinical characteristics of the participants.
Variables Statistic
N participants 229
Demographic characteristics
N (%) men 146 (64)
mean age (SD) in years 63.9 (10.2)
N (%) married or living together 185 (81)
N (%) higher educated (vs. low to intermediate) 105 (46)
Clinical characteristics
Status of use
N (%) starters (b3 months) 21 (9)
N (%) users (N3 months) 189 (83)
N (%) discontinued 19 (8)
Duration of use (only users)
N (%) 0–1 years 23 (12)
N (%) 1–4 years 64 (34)
N (%) 4 years or longer 102 (54)
Name of statin treatment
N (%) atorvastatin 41 (18)
N (%) ﬂuvastatin 2 (1)
N (%) pravastatin 19 (8)
N (%) rosuvastatin 27 (12)
N (%) simvastatin 140 (61)
Primary vs. secondary prevention
Primary prevention
N (%) elevated cholesterol 117 (51)
N (%) diabetes 37 (16)
Secondary prevention
N (%) MI/AP/TIA/Stroke/IC 81 (35)
N (%) PCI 31 (14)
N (%) CBAG 12 (5)
Abbreviations: MI, Myocardial Infarction; AP, Angina Pectoris; TIA, Transient Ischemic
Attack; IC, Intermittent Claudication, PCI, Percutaneous Coronary Intervention; CBAG, Cor-
onary Bypass Artery Grafting.
The relative importance of each attribute is calculated as follows: for each attribute the
difference between the utilities of its levels is divided by the sum of the differences
between the utilities for all of the attributes and multiplied by 100.Furthermore patients' trade-offs may help physicians to identify patients
at risk for intentional non-adherence forwhom amore persuasive expla-
nation of the efﬁcacy of statins or resolution of negative perceptions of
side effects might be fruitful. On the other hand, the ﬁnding that many
patients seemed to value the efﬁcacy equally or less important than the
side effects and other drawbacks could also suggest that there is
overprescribing from a patient's perspective. Particularly for these pa-
tients, alternative prevention strategies aimed at changing modiﬁable
lifestyle risk factors should be discussed between a physician and a pa-
tient. Considering patients' trade-offs is all the more important because
the American College of Cardiology and the American Heart Association
recently liberalized the boundary for statin therapy initiation but also ac-
knowledged that decisions to initiate statins should not be solely based
on passing a certain atherosclerotic cardiovascular disease risk threshold,
but should be based on a shared decision making process in which phy-
sicians and patients weigh the potential beneﬁts against the side effects
and practical inconveniences [8]. The assessment of patients' trade-off
preferences about cardiovascular drugs in larger-scale longitudinal stud-
ies and clinical practice is therefore strongly encouraged.Conﬂicts of interest
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